Clinical Trials Logo

Clinical Trial Summary

Patients with permanent or persistent atrial fibrillation require rate control medication to prevent excessive tachycardia. Since too much medication leads to a lower than expected heart rate (low output and symptoms) and too little leads to a fast heart rate (with associated symptoms), finding the ideal medication level (target that could fluctuate) is vital for patient's wellbeing. Clinicians adjust the medication each time patients come into the clinic (once or twice a year). In between those visits, medication is not changed even though patients would benefit for some incremental medication adjustment. Patients implanted with Biotronik devices have access to Home Monitoring® (HM), a user friendly remote monitoring system transmitting daily device and patient information to clinicians. Heart rate and activity hours can be tracked and this information could be used to adjust medication. In a step by step process, patients will gradually gain autonomy in the weekly adjustment of their rate control medication. In order to guide medication adjustment by patients, the research team will filter and simplify the information received by HM before sending it to patients. It is hypothesize that patient empowerment, understanding the dynamics of their heart rates in relation to the amount of medication used, will lead to better heart rate control, and it will improve the daily hours of patients activity.


Clinical Trial Description

Patients with permanent or persistent atrial fibrillation require rate control medication to prevent heart rate (HR) speed up. Beta-blockers or calcium channel blockers are used to achieve a reasonable HR; symptoms, EKG and Holter recordings guide clinicians to rate control targets at clinical encounters (at our pacemaker clinic at 6 to 12 months intervals). Once a target HR is achieved, unless new symptoms arise, medication is seldom modified. Rate control medications need to be well adjusted: if not enough dose administered, HR will increase, leading to palpitations, shortness of breath and eventually heart failure; if too much medication is given, patients would experience low cardiac output symptoms (fatigue, tiredness, shortness of breath, low blood pressure, and eventually syncope). Clinicians tend to over control heart rates with no added benefits. Most of patients with a pacemaker or defibrillator at our center are offered a remote monitoring system as part of a regular follow up schema at our pacemaker clinic; usually to reduce in face encounters, and to be alerted if a problem arises with the pacemaker or defibrillator. There are many remote monitoring systems (five, one for each vendor implanted at our center), and the Home Monitoring® (HM) from Biotronik is specially friendly as all information from the device (pacemaker or defibrillator) is transmitted every day to our clinic with no interaction from the patient side. Beside device status itself (remaining battery, system integrity) daily mean heart rates (measured in beats per minute: bpm) and patient activity (measured as hours per day in activity, as detected by the movement or activity sensor implanted in the device) are also transmitted, but if HR are between safety boundaries (programmed for each patient after implant), all information is rarely used for any other purpose. If patients with permanent or persistent atrial fibrillation, rate control stable medication, and a HM pacemaker, are followed closely (every week) to adjust the medication (every week if needed, by the research team at the beginning) based on mean heart rates and daily activities already received, we hypothesize that patients will achieve not only better rate control targets, but they will increase their hours of activity per day. Eventually once the patient has understood the principle, medication adjustment would be done by the patient itself based on the same simple information redirected to him or her. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05066971
Study type Interventional
Source Université de Sherbrooke
Contact Felix Alejandro Ayala Paredes, MD PhD
Phone +1 819 3461110
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date November 1, 2021
Completion date June 15, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04544397 - Outcomes of Second Generation Laser Balloon Ablation for Atrial Fibrillation
Recruiting NCT04473963 - FLOW-AF: A Study to Evaluate the Ablacon Electrographic FLOW EGF Technology N/A
Recruiting NCT04045067 - Low-voltage Areas Defragmentation in Sinus Rhythm for Radiofrequency Ablation of Persistent Atrial Fibrillation
Recruiting NCT04715425 - Thoracoscopic Surgical Versus Catheter Ablation Approaches for Primary Treatment of Persistent Atrial Fibrillation N/A
Enrolling by invitation NCT04148625 - Subxyphoid Hybrid MAZE Registry for Patients With Persistent Atrial Fibrillation
Recruiting NCT04606693 - Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates N/A
Recruiting NCT04342312 - Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation
Recruiting NCT04542785 - Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial N/A
Recruiting NCT04237389 - Thoracoscopic Ablation Versus Catheter Ablation in Patients With Atrial Fibrillation N/A
Recruiting NCT04206917 - MultiPulse Therapy (MPT) for AF N/A
Recruiting NCT04229160 - Noninvasive 3D Mapping in Persistent Atrial Fibrillation, to Describe Modifications of the Arrhythmogenic Substrate After Pulmonary Vein Isolation and Identify Potential Predicting Factors of Ablation Success N/A
Completed NCT03987204 - Ivabradine for Rate Control in Permanent Atrial Fibrillation Phase 1
Completed NCT04500184 - Exercise-based Cardiac Rehabilitation After Thoracoscopic Ablation in Patients With Persisent Atrial Fibrillation
Active, not recruiting NCT04148664 - A Trial of High Power-Short Duration Versus Standard Power-Long Duration Radiofrequency Ablation for Treatment of Atrial Fibrillation N/A
Recruiting NCT04508491 - Cognitive Function in Patients With Persisted Atrial Fibrillation N/A
Not yet recruiting NCT04942834 - Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation N/A
Not yet recruiting NCT04489004 - The Chinese Registration Study of Driver Ablation of Persistent Atrial Fibrillation. N/A
Recruiting NCT04832646 - VOLTage Mapping in Atrial Fibrillation